REL

From Wikipedia, the free encyclopedia

V-rel reticuloendotheliosis viral oncogene homolog (avian)

Identifiers

REL; C-Rel

External IDs

OMIM: 164910 MGI: 97897 HomoloGene: 2182

Gene ontology
Molecular Function:	• transcription factor activity • signal transducer activity • protein binding
Cellular Component:	• nucleus
Biological Process:	• cytokine production • regulation of transcription, DNA-dependent • transcription from RNA polymerase II promoter • positive regulation of I-kappaB kinase/NF-kappaB cascade • positive regulation of interleukin-12 biosynthetic process • positive regulation of transcription, DNA-dependent

RNA expression pattern

More reference expression data

Orthologs

Human

Mouse

Refseq

NM_002908 (mRNA)
NP_002899 (protein)

NM_009044 (mRNA)
NP_033070 (protein)

Location

Chr 2: 60.96 - 61 Mb

Chr 11: 23.64 - 23.67 Mb

Pubmed search

[1]

[2]

v-rel reticuloendotheliosis viral oncogene homolog (avian), also known as REL, is a human gene. The protein encoded by the human REL gene is a member of the NF-κB family of transcription factors. The REL gene is amplified or mutated in several human B-cell lymphomas, including diffuse large B-cell lymphomas and Hodgkin's lymphomas.

[edit] Further reading

Rayet B, Gélinas C (2000). "Aberrant rel/nfkb genes and activity in human cancer.". Oncogene 18 (49): 6938–47. doi:10.1038/sj.onc.1203221. PMID 10602468.
Kunsch C, Ruben SM, Rosen CA (1992). "Selection of optimal kappa B/Rel DNA-binding motifs: interaction of both subunits of NF-kappa B with DNA is required for transcriptional activation.". Mol. Cell. Biol. 12 (10): 4412–21. PMID 1406630.
Neumann M, Tsapos K, Scheppler JA, et al. (1992). "Identification of complex formation between two intracellular tyrosine kinase substrates: human c-Rel and the p105 precursor of p50 NF-kappa B.". Oncogene 7 (11): 2095–104. PMID 1437141.
Kochel T, Rice NR (1992). "v-rel- and c-rel-protein complexes bind to the NF-kappa B site in vitro.". Oncogene 7 (3): 567–72. PMID 1549370.
Ruben SM, Klement JF, Coleman TA, et al. (1992). "I-Rel: a novel rel-related protein that inhibits NF-kappa B transcriptional activity.". Genes Dev. 6 (5): 745–60. PMID 1577270.
Kumar S, Rabson AB, Gélinas C (1992). "The RxxRxRxxC motif conserved in all Rel/kappa B proteins is essential for the DNA-binding activity and redox regulation of the v-Rel oncoprotein.". Mol. Cell. Biol. 12 (7): 3094–106. PMID 1620118.
Lu D, Thompson JD, Gorski GK, et al. (1991). "Alterations at the rel locus in human lymphoma.". Oncogene 6 (7): 1235–41. PMID 1650444.
Muchardt C, Seeler JS, Nirula A, et al. (1992). "Regulation of human immunodeficiency virus enhancer function by PRDII-BF1 and c-rel gene products.". J. Virol. 66 (1): 244–50. PMID 1727488.
Hansen SK, Nerlov C, Zabel U, et al. (1992). "A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene.". EMBO J. 11 (1): 205–13. PMID 1740106.
Davis N, Ghosh S, Simmons DL, et al. (1991). "Rel-associated pp40: an inhibitor of the rel family of transcription factors.". Science 253 (5025): 1268–71. PMID 1891714.
Lim MY, Davis N, Zhang JY, Bose HR (1990). "The v-rel oncogene product is complexed with cellular proteins including its proto-oncogene product and heat shock protein 70.". Virology 175 (1): 149–60. PMID 2155506.
Brownell E, Mittereder N, Rice NR (1989). "A human rel proto-oncogene cDNA containing an Alu fragment as a potential coding exon.". Oncogene 4 (7): 935–42. PMID 2666912.
Brownell E, O'Brien SJ, Nash WG, Rice N (1986). "Genetic characterization of human c-rel sequences.". Mol. Cell. Biol. 5 (10): 2826–31. PMID 3016517.
Brownell E, Kozak CA, Fowle JR, et al. (1986). "Comparative genetic mapping of cellular rel sequences in man, mouse, and the domestic cat.". Am. J. Hum. Genet. 39 (2): 194–202. PMID 3529946.
John S, Reeves RB, Lin JX, et al. (1995). "Regulation of cell-type-specific interleukin-2 receptor alpha-chain gene expression: potential role of physical interactions between Elf-1, HMG-I(Y), and NF-kappa B family proteins.". Mol. Cell. Biol. 15 (3): 1786–96. PMID 7862168.
Xu X, Gélinas C (1995). "The v-Rel oncoprotein complexes with new Rel- and RelA-related proteins in transformed cells.". Virology 207 (2): 362–8. doi:10.1006/viro.1995.1095. PMID 7886940.
Mackman N (1994). "Protease inhibitors block lipopolysaccharide induction of tissue factor gene expression in human monocytic cells by preventing activation of c-Rel/p65 heterodimers.". J. Biol. Chem. 269 (42): 26363–7. PMID 7929355.
Sif S, Gilmore TD (1994). "Interaction of the v-Rel oncoprotein with cellular transcription factor Sp1.". J. Virol. 68 (11): 7131–8. PMID 7933095.
Hansen SK, Baeuerle PA, Blasi F (1994). "Purification, reconstitution, and I kappa B association of the c-Rel-p65 (RelA) complex, a strong activator of transcription.". Mol. Cell. Biol. 14 (4): 2593–603. PMID 8139561.
Beg AA, Baldwin AS (1994). "Activation of multiple NF-kappa B/Rel DNA-binding complexes by tumor necrosis factor.". Oncogene 9 (5): 1487–92. PMID 8152812.

[edit] External links

MeSH Genes,+rel

This article on a gene on chromosome 2 is a stub. You can help Wikipedia by expanding it.

v • d • e

Transcription factors and intracellular receptors

(1) Basic domains

(1.1) Basic leucine zipper (bZIP)	Activating transcription factor (AATF, 1, 2, 3, 4, 5, 6, 7) • AP-1 (c-Fos, FOSB, FOSL1, FOSL2, c-Jun, JUNB, JUND) • BACH (1, 2) • BATF • BLZF1 • C/EBP (α, β, γ, δ, ε, ζ) • CREB (1, 3, L1) • CREM • DBP • DDIT3 • GABPA • HLF • MAF (B, F, G, K) • NFE (2, L1, L2) • NRL • NRF1 • XBP1

(1.2) Basic helix-loop-helix (bHLH)	ATOH1 • AhR • AHRR • ARNT • ASCL1 • BHLHB2 • BMAL (ARNTL, ARNTL2) • CLOCK • EPAS1 • HAND (1, 2) • HES (5, 6) • HEY (1, 2, L) • HES1 • HIF (1A, 3A) • ID (1, 2, 3, 4) • LYL1 • MXD4 • MYCL1 • MYCN • Myogenic regulatory factors (MyoD, Myogenin, MYF5, MYF6) • Neurogenins • NeuroD (1, 2) • NPAS (1, 2, 3) • OLIG (1, 2) • Scleraxis • TAL1 • Twist • USF1

(1.3) bHLH-ZIP	MAX • MITF • MNT • MLX • MXI1 • Myc • SREBP (1, 2)

(1.6) Basic helix-span-helix (bHSH)	AP-2

(2) Zinc finger
DNA-binding domains

(2.1) Nuclear receptor (Cys₄)	subfamily 1 (Thyroid hormone (α, β), CAR, FXR, LXR (α, β), PPAR (α, β/δ, γ), PXR, RAR (α, β, γ), ROR (α, β, γ), Rev-ErbA (α, β), VDR) • subfamily 2 (COUP-TF (I, II), Ear-2, HNF4 (α, γ), PNR, RXR (α, β, γ), Testicular receptor (2, 4), TLX) • subfamily 3 (Steroid hormone (Estrogen (α, β), Estrogen related (α, β, γ), Androgen, Glucocorticoid, Mineralocorticoid, Progesterone)) • subfamily 4 NUR (NGFIB, NOR1, NURR1) • subfamily 5 (LRH-1, SF1) • subfamily 6 (GCNF) • subfamily 0 (DAX1, SHP)

(2.2) Other Cys₄	GATA (1, 2, 3, 4, 5, 6) • MTA (1, 2, 3)

(2.3) Cys₂His₂	ATBF1 • BCL(6, 11A, 11B) • CTCF • E4F1 • EGR (2, 3) • ERV3 • General transcription factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF: 1, 2, TFIIH: 1, 2, 4, 2I, 3A, 3C1, 3C2) • GFI1 • GLI-Krüppel family (1, 2, 3, YY1) • HIC (1, 2) • HIVEP (1, 2, 3) • IKZF (1, 2, 3) • ILF (2, 3) • KLF (2, 4, 5, 6, 9, 10, 11, 12, 13) • MTF1 • MYT1 • OSR1 • Sp1 • zinc finger ((3, 7, 9, 10, 19, 22, 24, 33B, 34, 35, 41, 43, 44, 51, 74, 143, 146, 148, 165, 202, 217, 219, 238, 239, 259, 267, 268, 281, 295, 318, 330, 346, 350, 365, 366, 384, 451, 452, 471, 593, 638, 649, 655) • Zbtb7 (7A) • ZBT (16, 17, 33)

(2.4) Cys₆	HIVEP1

(2.5) Alternating composition	AIRE • DIDO1 • GRLF1 • ING (1, 2, 4) • JARID (1A, 1B, 1C, 1D, 2) • JMJD1B

(3) Helix-turn-helix
domains

(3.1) Homeo domain	ARX • CDX (1, 2) • CRX • CUTL1 • DLX (3, 4, 5) • EMX2 • EN (1, 2) • FHL (1, 2, 3) • HESX1 • HHEX • HLX • Homeobox (A1, A3, A4, A5, A7, A9, A10, A11, A13, B1, B2, B3, B4, B5, B6, B7, B8, B9, B13, C4, C5, C6, C8, C9, C10, C11, C13, D1, D3, D4, D8, D9, D10, D11, D12, D13) • HOPX • MEIS (1, 2) • MEOX2 • MNX1 • MSX (1, 2) • NANOG • NKX (2-1, 2-5, 3-1) • PHF (3, 6, 10, 17) • POU domain (PIT-1, BRN-3: 1, 2, Octamer transcription factor: 1, 2, 3/4, 6, 7) • OTX (1, 2) • PDX1

(3.2) Paired box	PAX (1, 2, 3, 4, 5, 6, 7, 8, 9)

(3.3) Fork head / winged helix	E2F (1, 2, 3, 4, 5) • FOX proteins (C1, C2, E1, G1, H1, K2, L2, M1, N3, O1A, , O3A, O4, P1, P2, P3)

(3.4) Heat Shock Factors	HSF (1, 2, 4)

(3.5) Tryptophan clusters	ELF (4, 5) • EGF • ELK (1, 3, 4) • ERF • ERG • ETS (1, 2) • ETV (1, 4, 5, 6) • FLI1 • Interferon regulatory factors (1, 2, 3, 4, 5, 6, 7, 8) • MYB • MYBL2

(3.6) TEA domain	transcriptional enhancer factor 1, 2

(4) β-Scaffold factors with
minor groove contacts

(4.1) Rel homology region	NF-κB (NFKB1, NFKB2, REL, RELA, RELB) • NFAT (C1, C2, C3, C4, 5)

(4.2) STAT	STAT (1, 2, 3, 4, 5, 6)

(4.3) p53	p53

(4.4) MADS box	Mef2 (A, B, C, D) • SRF

(4.7) High mobility group	HNF (1A, 1B) • LEF1 • SOX (2, 3, 4, 5, 6, 8, 9, 10, 11, 13, 15, 18) • SRY • SSRP1

(4.10) Cold-shock domain	CSDA, YBX1

(4.11) Runt	CBF (CBFA2T2, CBFA2T3, RUNX1, RUNX2, RUNX3, RUNX1T1)

(0) Other
transcription factors

(0.2) HMGI(Y)	HMGA (1, 2) • HBP1

(0.3) Pocket domain	Rb • RBL1 • RBL2

(0.5) AP-2/EREBP-related factors	Apetala 2 • EREBP • B3

(0.6) Miscellaneous	ARID (1A, 1B, 2, 3A, 3B, 4A) • CAP • IFI (16, 35) • MLL (2, 3, T1) • MNDA • NFI (A, B, C, X) • NFY (A, B, C) • Rho/Sigma • R-SMAD